Pharmacokinetics and Safety Study of HN0037, a Novel Anti‐Human Herpes Simplex Virus Inhibitor, in Healthy Volunteers
Jie Hou(Dalian Medical University), George J. Hill(Regend Therapeutics (China)), Yujing Di(Luye Pharma (China)), Ying‐Zhe Fan(Shanghai University of Traditional Chinese Medicine), Xin Zhou(Changchun University), Donghui Qin(Regend Therapeutics (China)), Lu Wang(Children's Hospital of Philadelphia), Hong Gao(Regend Therapeutics (China)), Yi Zhou(Tongji Hospital), Ying Wang(Lanzhou City University), Meng Qin(Ministry of Education of the People's Republic of China)
Cited by 9
Related Papers
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
|Clinical Infectious Diseases|2020|501
BATF–JUN is critical for IRF4-mediated transcription in T cells
|Nature|2012|473
Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages
|Nature Immunology|2011|471